FDA Approves OXCARBAZEPINE — Advagen Pharma Ltd.

Advagen Pharma Ltd. announced the March 5 FDA approval of its ANDA207717 for the oral formulation of oxycarbazepine, providing clearance to market the anticonvulsant generic. The clearance is expected to intensify price competition against the leading brand within the epilepsy treatment market and diversify the company's product portfolio.